Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2022-05-19 00:00:00 ET · period of report 2022-05-18 · accession 0001104659-22-062916 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-19 | 2022-05-18 | APRE | SCHADE CHRISTIAN S | COB, CEO, Dir | P - Purchase | $0.64 | +37.5K | 292.6K | +15% | +$24.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-18 | P | A | 37,500 | $0.64 | 292,616 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |